<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8809320</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1600</journal-id>
<journal-id journal-id-type="nlm-ta">Neuron</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuron</journal-id>
<journal-title-group>
<journal-title>Neuron</journal-title>
</journal-title-group>
<issn pub-type="ppub">0896-6273</issn>
<issn pub-type="epub">1097-4199</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28669545</article-id>
<article-id pub-id-type="pmc">5548138</article-id>
<article-id pub-id-type="doi">10.1016/j.neuron.2017.06.018</article-id>
<article-id pub-id-type="manuscript">NIHMS885313</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Retrograde synaptic inhibition is mediated by α-Neurexin binding to the α2δ subunits of N-type calcium channels</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tong</surname>
<given-names>Xia-Jing</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>López-Soto</surname>
<given-names>Eduardo Javier</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Haowen</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nedelcu</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lipscombe</surname>
<given-names>Diane</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Zhitao</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaplan</surname>
<given-names>Joshua M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA</aff>
<aff id="A2">
<label>2</label>Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA</aff>
<aff id="A3">
<label>3</label>Program in Neuroscience, Harvard Medical School</aff>
<aff id="A4">
<label>4</label>Department of Neuroscience and Brown Institute for Brain Science, Brown University, Providence, RI 02912</aff>
<aff id="A5">
<label>5</label>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Australia</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Lead contact. Correspondence to: <email>kaplan@molbio.mgh.harvard.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>19</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>95</volume>
<issue>2</issue>
<fpage>326</fpage>
<lpage>340.e5</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuron.2017.06.018-->
<abstract>
<title>Summary</title>
<p id="P1">The synaptic adhesion molecules Neurexin and Neuroligin alter the development and function of synapses and are linked to autism in humans. In <italic>C. elegans</italic>, post-synaptic Neurexin (NRX-1) and pre-synaptic Neuroligin (NLG-1) mediate a retrograde synaptic signal that inhibits acetylcholine (ACh) release at neuromuscular junctions. Here we show that the retrograde signal decreases ACh release by inhibiting the function of pre-synaptic UNC-2/CaV2 calcium channels. Post-synaptic NRX-1 binds to an auxiliary subunit of pre-synaptic UNC-2/CaV2 channels (UNC-36/α2δ) decreasing UNC-36 abundance at pre-synaptic elements. Retrograde inhibition is mediated by a soluble form of NRX-1’s ectodomain, which is released from the post-synaptic membrane by the SUP-17/ADAM10 protease. Mammalian Neurexin-1α binds α2δ–3 and decreases CaV2.2 current in transfected cells whereas Neurexin-1α has no effect on CaV2.2 reconstituted with α2δ1 and α2δ2. Collectively, these results suggest that α-Neurexin binding to α2δ is a conserved mechanism for regulating synaptic transmission.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>